A Spontaneous Brugada Pattern, No Symptoms: Defibrillator or Further Testing
A single patient whose ECG carries a pattern strongly linked to sudden death, found before a routine knee surgery rather than after any cardiac symptom at all. The disagreement is about whether that pattern alone justifies a defibrillator, or whether more information should come first.
D.R., a 41-year-old man, spends most weekday evenings in his basement working on an increasingly elaborate model train layout he started during a stretch of bad weather two winters ago and never really stopped expanding. He has mild, recently noted hypertension not yet treated, and no other cardiac history. A pre-operative ECG ahead of a scheduled knee arthroscopy showed at least 2 mm of coved ST-segment elevation with an inverted T wave in the right precordial leads, confirmed on repeat tracing without any fever or provoking drug on board — the definition of a spontaneous Type 1 Brugada pattern, not one that only appears under provocation. He has never fainted, has no family history of sudden cardiac death that he's aware of, and the finding was entirely incidental to a surgery for an unrelated knee injury.
A spontaneous Type 1 Brugada pattern carries a real, elevated risk of ventricular arrhythmia and sudden death compared with a pattern that only emerges with fever or a provoking drug, but the actual annual event rate in someone with no symptoms and no family history is genuinely lower than in Brugada patients who present after syncope or a documented arrhythmia. That gap is exactly where the team's disagreement lives, and it isn't the only decision in front of them — a defined list of medications and situations, starting with ordinary fever, can unmask or worsen the pattern regardless of what's decided about a defibrillator. He has already asked, reasonably, whether his upcoming knee surgery is even still safe to proceed with, a question the anesthesia team will need this chart to answer clearly before he's back on their schedule.
A spontaneous pattern with no other evidence yet
A spontaneous Type 1 pattern is the higher-risk version of this diagnosis, not the incidental, provoked kind that shows up only with fever. Sudden death can be a first presentation in Brugada syndrome, and I don't think we should wait for a symptom that, by definition, might not give him a second chance to report it. I'd recommend a defibrillator now.
I'd risk-stratify before committing him to a device. His annual event rate as an asymptomatic patient with no family history is genuinely lower than the population that drove the earliest alarming reports about spontaneous Type 1 patterns, which were weighted toward patients who'd already had a symptom. An electrophysiology study, assessing whether ventricular arrhythmia is inducible, adds real information here — and he's 41, with decades of device-related complications ahead of him if we implant now and the additional testing would have argued against it.
I understand wanting more data, but inducibility on EPS has its own real controversy as a predictor in Brugada specifically — it doesn't resolve this as cleanly as an EPS does in some other arrhythmia syndromes, and I don't want us to treat a negative study as more reassuring than it actually is.
Regardless of how the device question resolves, two things belong in his chart today. First, a specific avoid-list, and it should name drugs rather than categories: the Class I sodium-channel blockers above all — flecainide, propafenone, procainamide, ajmaline — along with tricyclic antidepressants such as amitriptyline and nortriptyline, lithium, and cocaine. For his knee surgery specifically, the anesthesia team needs to know that bupivacaine and propofol both appear on published caution lists, which changes how they plan his case rather than whether it can go ahead. He should carry that list into every future medical encounter. Second, fever management needs to be aggressive and proactive, not reactive — fever itself is one of the most common Brugada-pattern triggers, and a low threshold for antipyretics is a real, actionable recommendation independent of anything the device debate settles. He should also be told plainly that a fever high enough to need treatment is a reason to be seen and have an ECG, not just to take acetaminophen at home. If he or the EPS findings ultimately favor avoiding an ICD, quinidine has genuine evidence for reducing arrhythmic burden in Brugada syndrome and is worth naming now as a real alternative, not an afterthought.
Electrophysiology study scheduled for further risk stratification rather than proceeding straight to a defibrillator. A named-drug avoid-list was placed in his chart immediately and given to him directly, flagged specifically to the anesthesia team for his upcoming knee surgery, and a low threshold for antipyretic use was set regardless of how the device decision resolves, along with instructions to seek evaluation and an ECG rather than self-treat a significant fever.
The two electrophysiologists left disagreeing about how much weight an EPS result should carry in Brugada syndrome specifically — a genuine, acknowledged limitation of the test in this condition that neither treated as settled by proceeding with it anyway.